Amriti R. Lulla

897 total citations
24 papers, 434 citations indexed

About

Amriti R. Lulla is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Amriti R. Lulla has authored 24 papers receiving a total of 434 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Molecular Biology and 5 papers in Cancer Research. Recurrent topics in Amriti R. Lulla's work include Cancer-related Molecular Pathways (9 papers), Cancer therapeutics and mechanisms (4 papers) and Cell death mechanisms and regulation (4 papers). Amriti R. Lulla is often cited by papers focused on Cancer-related Molecular Pathways (9 papers), Cancer therapeutics and mechanisms (4 papers) and Cell death mechanisms and regulation (4 papers). Amriti R. Lulla collaborates with scholars based in United States, United Kingdom and France. Amriti R. Lulla's co-authors include Wafik S. El‐Deiry, David T. Dicker, Joshua E. Allen, Marie D. Ralff, Avital Lev, C. Leah B. Kline, Jessica Wagner, Varun V. Prabhu, Philip H. Abbosh and Shengliang Zhang and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Amriti R. Lulla

21 papers receiving 431 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amriti R. Lulla United States 11 277 135 97 60 43 24 434
Jiang‐Jie Duan China 10 227 0.8× 229 1.7× 219 2.3× 41 0.7× 23 0.5× 15 481
Da Pan China 5 209 0.8× 282 2.1× 178 1.8× 24 0.4× 30 0.7× 5 413
Jianqun Liao United States 10 340 1.2× 257 1.9× 149 1.5× 39 0.7× 44 1.0× 14 642
Zaili Luo China 11 241 0.9× 77 0.6× 95 1.0× 52 0.9× 20 0.5× 15 367
Ilenia Segatto Italy 14 290 1.0× 251 1.9× 198 2.0× 51 0.8× 13 0.3× 23 536
C-T Yeh Taiwan 7 277 1.0× 75 0.6× 68 0.7× 77 1.3× 20 0.5× 7 389
Jacqueline Sayyah United States 9 368 1.3× 178 1.3× 78 0.8× 21 0.3× 37 0.9× 11 534
Meiou Dai Canada 15 470 1.7× 300 2.2× 161 1.7× 76 1.3× 15 0.3× 21 703
Denis Alférez United Kingdom 12 340 1.2× 300 2.2× 127 1.3× 40 0.7× 13 0.3× 17 551
Petra Ohneseit Germany 10 258 0.9× 126 0.9× 110 1.1× 41 0.7× 16 0.4× 14 460

Countries citing papers authored by Amriti R. Lulla

Since Specialization
Citations

This map shows the geographic impact of Amriti R. Lulla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amriti R. Lulla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amriti R. Lulla more than expected).

Fields of papers citing papers by Amriti R. Lulla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amriti R. Lulla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amriti R. Lulla. The network helps show where Amriti R. Lulla may publish in the future.

Co-authorship network of co-authors of Amriti R. Lulla

This figure shows the co-authorship network connecting the top 25 collaborators of Amriti R. Lulla. A scholar is included among the top collaborators of Amriti R. Lulla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amriti R. Lulla. Amriti R. Lulla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Mi, Amriti R. Lulla, Spyros Tsavachidis, et al.. (2024). Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Research. 84(22). 3864–3880. 4 indexed citations
2.
Lulla, Amriti R., Saïd Akli, Cansu Karakaş, et al.. (2023). Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis. Molecular Cancer Therapeutics. 23(4). 492–506. 10 indexed citations
3.
Lulla, Amriti R., Tuyen Duong Thanh Nguyen, Mi Li, et al.. (2023). Abstract 950: Targeting PKMYT1 kinase is an effective treatment strategy in triple negative breast cancers with low molecular weight cyclin E (LMW-E) expression. Cancer Research. 83(7_Supplement). 950–950. 3 indexed citations
4.
Akli, Saïd, Amriti R. Lulla, Natalie W. Fowlkes, et al.. (2022). Abstract 2592: Aurora kinase is an actionable target in low molecular weight cyclin E induced mammary tumors. Cancer Research. 82(12_Supplement). 2592–2592. 1 indexed citations
5.
Lulla, Amriti R., Yan Zhou, Marie D. Ralff, et al.. (2022). miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.. PubMed. 12(1). 315–326. 2 indexed citations
6.
Tian, Xiaobing, Nagib Ahsan, Amriti R. Lulla, et al.. (2021). P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9. Neoplasia. 23(3). 304–325. 17 indexed citations
7.
Lulla, Amriti R., Saïd Akli, Cansu Karakaş, et al.. (2021). LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis. 10(5). 4 indexed citations
8.
Lev, Avital, Amriti R. Lulla, Brian C. Ross, et al.. (2018). ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. Molecular Cancer Research. 16(5). 754–766. 22 indexed citations
9.
Lulla, Amriti R., Michael Slifker, Yan Zhou, et al.. (2017). miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells. Cancer Research. 77(24). 6902–6913. 44 indexed citations
10.
Prabhu, Varun V., Amriti R. Lulla, Neel S. Madhukar, et al.. (2017). Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS ONE. 12(8). e0180541–e0180541. 30 indexed citations
11.
Lulla, Amriti R., Margret B. Einarson, Yan Zhou, David T. Dicker, & Wafik S. El‐Deiry. (2017). Abstract 5455: Novel miRNA-based therapeutic approach to selectively target mutant p53 in cancer. Cancer Research. 77(13_Supplement). 5455–5455. 1 indexed citations
12.
13.
Kline, C. Leah B., Marie D. Ralff, Amriti R. Lulla, et al.. (2017). Role of Dopamine Receptors in the Anticancer Activity of ONC201. Neoplasia. 20(1). 80–91. 94 indexed citations
14.
Wagner, Jessica, C. Leah B. Kline, Marie D. Ralff, et al.. (2017). Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 16(19). 1790–1799. 56 indexed citations
15.
Lev, Avital, Amriti R. Lulla, David T. Dicker, & Wafik S. El‐Deiry. (2017). Abstract 2102: ONC201 targets AR and AR-V7 signaling pathways, reduces PSA and synergizes with everolimus in castration resistant prostate cancer. Cancer Research. 77(13_Supplement). 2102–2102. 1 indexed citations
16.
Lev, Avital, Amriti R. Lulla, Jessica Wagner, et al.. (2017). Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget. 8(47). 81776–81793. 37 indexed citations
17.
Lev, Avital, Amriti R. Lulla, Jessica Wagner, David T. Dicker, & Wafik S. El‐Deiry. (2017). Abstract 1067: Anti-cancer efficacy of imipridones in pancreatic cancer: single agent ONC212 or combination of ONC201 with IGF1-R inhibition. Cancer Research. 77(13_Supplement). 1067–1067. 1 indexed citations
18.
Lev, Avital, Safoora Deihimi, Elena Shagisultanova, et al.. (2017). Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biology & Therapy. 18(9). 694–704. 14 indexed citations
19.
Prabhu, Varun V., Bo Hong, Joshua E. Allen, et al.. (2016). Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation. Cancer Research. 76(7). 1989–1999. 49 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiang‐Jie Duan Breakdown of academic impact, for papers by Da Pan Breakdown of academic impact, for papers by Jianqun Liao Breakdown of academic impact, for papers by Zaili Luo Breakdown of academic impact, for papers by Ilenia Segatto Breakdown of academic impact, for papers by C-T Yeh Breakdown of academic impact, for papers by Jacqueline Sayyah Breakdown of academic impact, for papers by Meiou Dai Breakdown of academic impact, for papers by Denis Alférez Breakdown of academic impact, for papers by Petra Ohneseit
Rankless by CCL
2026